Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLijuan Deng, Jun Zhu, Zhiming Li et al.|Blood Advances|2023Cited by 30
Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia PatientsDaobin Zhou, Xiangyang Zhang, Jie Jin et al.|Blood|2021Cited by 11